BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 31,543 shares of BridgeBio Pharma stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02. Following the transaction, the chief executive officer now owns 211,718 shares in the company, valued at approximately $7,651,488.52. This trade represents a 12.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Neil Kumar also recently made the following trade(s):
- On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28.
BridgeBio Pharma Trading Up 0.1 %
NASDAQ:BBIO traded up $0.04 on Friday, hitting $36.85. 2,508,887 shares of the company's stock traded hands, compared to its average volume of 2,930,747. The firm has a 50-day moving average price of $31.71 and a 200-day moving average price of $27.85. The company has a market cap of $6.96 billion, a PE ratio of -15.29 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. On average, research analysts forecast that BridgeBio Pharma, Inc. will post -2.56 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently commented on BBIO shares. Bank of America boosted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. Scotiabank increased their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Friday. Cantor Fitzgerald restated an "overweight" rating and issued a $95.00 target price on shares of BridgeBio Pharma in a report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Finally, Citigroup lifted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $51.67.
Check Out Our Latest Report on BridgeBio Pharma
Hedge Funds Weigh In On BridgeBio Pharma
A number of hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after purchasing an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of BridgeBio Pharma during the 4th quarter worth about $41,000. Sterling Capital Management LLC lifted its holdings in shares of BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after buying an additional 1,514 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $57,000. Finally, CWM LLC increased its holdings in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company's stock worth $88,000 after buying an additional 1,964 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
